Treatment of Glomerulonephritis in a 13-Year-Old
Treatment depends critically on the specific type of glomerulonephritis, but for the most common form in this age group—acute post-streptococcal glomerulonephritis (APSGN)—management is primarily supportive with diuretics and antihypertensives, while immunosuppression is reserved only for crescentic or rapidly progressive disease. 1
Initial Diagnostic Approach
The first step is determining whether this is infection-related GN (most common in children), IgA nephropathy, or another form requiring kidney biopsy. Key diagnostic indicators include:
- Acute GN presentation: Hematuria + proteinuria with edema, oliguria, or hypertension 1
- APSGN suspicion: Recent streptococcal/staphylococcal infection + transient hypocomplementemia (low C3) 1
- Essential workup: Urinalysis with sediment examination for dysmorphic RBCs and red cell casts, kidney function, serum albumin, complement C3, CBC, and renal ultrasound 1
When to Perform Kidney Biopsy
Biopsy is mandatory for 1:
- Atypical features
- Nephrotic syndrome presentation
- Persistently low C3 beyond 12 weeks
- Rapidly progressive glomerulonephritis (RPGN)
This is critical because misdiagnosis can occur—one recent case showed a 13-year-old initially diagnosed with IgA nephropathy who actually had C3 glomerulonephritis, only discovered on repeat biopsy after treatment failure 2.
Treatment Algorithm by Disease Type
For Acute Post-Streptococcal GN (Most Common)
Supportive care is the cornerstone 3, 1:
Fluid and sodium management:
- Dietary sodium restriction to <2.0 g/day (<90 mmol/day) 4
- Loop diuretics (furosemide) as first-line for edema, preferably twice daily dosing 4
- Escalate dose until clinically significant diuresis or maximum effective dose reached 4
Blood pressure control:
- Calcium channel blockers (nifedipine) for stage 2 hypertension 5, 1
- ACE inhibitors (captopril, enalapril) show superior BP control and echocardiographic improvement compared to other antihypertensives 5
Antibiotics:
- Only indicated for staphylococcus-associated GN, infective endocarditis-associated GN, or shunt nephritis 1
- No benefit of extended antimicrobial therapy over standard penicillin V for 10 days in preventing APSGN 5
Immunosuppression:
- Reserved exclusively for crescentic IRGN or rapidly progressive disease 1
- Evidence shows no advantage of combined immunosuppressants over supportive therapy alone in typical APSGN 5
For Other Forms Requiring Immunosuppression
If biopsy reveals IgA nephropathy, membranous nephropathy, or other primary GN forms, follow disease-specific KDIGO 2021 guidelines 4. The recent literature emphasizes emerging complement inhibitors and B-cell targeted therapies as steroid-sparing options 6.
For treatment-refractory C3 glomerulonephritis with persistent complement dysregulation, C3 inhibitors (pegcetacoplan) have shown rapid complete remission in pediatric cases 2.
Monitoring and Follow-Up
All patients require long-term monitoring 1:
- Serum creatinine
- Urinalysis for proteinuria and hematuria
- Blood pressure monitoring
- Target proteinuria goal: PCR <200 mg/g (<20 mg/mmol) or <8 mg/m²/hour in 24-hour urine 4
Crescentic or rapidly progressive GN patients need especially close surveillance as they risk progression to chronic kidney disease 1.
Critical Pitfalls to Avoid
- Don't delay biopsy in atypical presentations—waiting can miss alternative diagnoses requiring different treatment 2
- Don't use immunosuppression routinely in typical APSGN—evidence shows no benefit and adds unnecessary risk 5
- Don't accept proteinuria >200 mg/g as acceptable baseline without biopsy evidence of kidney scarring 4
- Monitor for diuretic complications: hypokalemia (loop/thiazide), hyponatremia (thiazide) 4
- Inpatient monitoring required for: significant edema, severe hypertension, or acute kidney injury 1
The prognosis for typical APSGN is excellent with supportive care alone 3, 5, but the small subset with crescentic disease requires aggressive intervention and lifelong nephrology follow-up 6, 1.